Immunomedics, Inc. (IMMU) ended last trading session with a change of 0.47 percent. It trades at an average volume of 3.43M shares versus 3.6M shares recorded at the end of last trading session. The share price of $6.37 is at a distance of 226.67 percent from its 52-week low and down -0.78 percent versus its peak. The company has a market cap of $640.5M and currently has 100.55M shares outstanding. The share price is currently 23.08 percent versus its SMA20, 40.35 percent versus its SMA50, and 90.92 percent versus its SMA200. The stock has a weekly performance of 29.21 percent and is 73.57 percent year-to-date as of the recent close.
On March 2, 2017 Immunomedics, Inc. (IMMU) announced that the Company offered venBio Select Advisor, LLC (“venBio”) a revised settlement proposal in connection with the Company’s 2016 Annual Meeting of Stockholders, which venBio has rejected.
The settlement proposal consisted of the following terms, along with other customary provisions:
- The immediate appointment of all four of venBio’s nominees to the Immunomedics Board of Directors to join four of Immunomedics’ director nominees;
- Jason Aryeh, Vice Chairman of the Board, and under the previously announced leadership succession plan, Chairman as of June 30, 2017, has offered to step down immediately in order to facilitate a stockholder-friendly settlement; and
- The previously initiated formal search for a new Chief Executive Officer would continue under the new Board.
TG Therapeutics, Inc. (TGTX) recently recorded 7.02 percent change and currently at $12.2 is 197.56 percent away from its 52-week low and down -3.17 percent versus its peak. It has a past 5-day performance of 19.61 percent and trades at an average volume of 1.5M shares. The stock has a 1-month performance of 144 percent and is 162.37 percent year-to-date as of the recent close. There were about 56.65M shares outstanding which made its market cap $691.13M. The share price is currently 83.05 percent versus its SMA20, 121.46 percent versus its SMA50, and 98.75 percent versus its SMA200.
On March 06, 2017 TG Therapeutics, Inc. (TGTX) announced positive topline results from its Phase 3 GENUINE clinical trial of TG-1101 (ublituximab) plus ibrutinib in patients with previously treated high risk Chronic Lymphocytic Leukemia (CLL). For the study, high risk was defined as having any one or more of the following: 17p deletion, 11q deletion or p53 mutation.
The multicenter, randomized trial (NCT02301156), which assessed the efficacy and safety of TG-1101 plus ibrutinib, met its primary endpoint, demonstrating a statistically significant improvement in Overall Response Rate (ORR) compared to ibrutinib alone in both the Intent to Treat (ITT) population (p=0.001) and Treated population (p<0.001). The ITT population includes all 126 randomized patients (64 in the TG-1101 + ibrutinib arm and 62 in the ibrutinib alone arm) while the Treated population includes all ITT patients that received at least one dose of either study drug (59 in the TG-1101 + ibrutinib arm and 58 in the ibrutinib alone arm).